Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05147272 · ClinicalTrials.gov registry record · Phase 1
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
A Phase 1 study, sponsored by Debiopharm International.
- Terminated
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT05147272: Clinical Trial Phase 1 study, sponsored by Debiopharm International.
NCT05147272 is a Phase 1 study that was terminated before completion, run by Debiopharm International. The registered enrollment target is 67 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05147272, a Phase 1 study, was terminated before completion, sponsored by Debiopharm International.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.
Primary Outcome
Incidence of grade 3 and above Treatment Related Emergent Adverse Events (TRAEs)
Interventions
- DRUG RP-6306 (oral PKMYT1 inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2024-08-28 |
| Phase | Phase 1 |
Why NCT05147272 stopped before completion
NCT05147272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher).
The record links to 0 conditions, and to 1 intervention - of which RP-6306 (oral PKMYT1 inhibitor) is the first listed.
NCT05147272 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05147272 about?
NCT05147272 is a clinical study titled "Study of RP-6306 With Gemcitabine in Advanced Solid Tumors". The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and pre...
What is the current status of trial NCT05147272?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2021-12-16. Estimated completion is 2024-08-28.
What interventions are being tested in trial NCT05147272?
The interventions under investigation include: RP-6306 (oral PKMYT1 inhibitor) (DRUG).
Who is sponsoring clinical trial NCT05147272?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05147272's enrollment target sits among peer trials
67 782nd of 2000 higher than 1,215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI